News and Announcements
Brisbane based proptech start-up Rent Rabbit secures $585,000 in seed round at $2m valuation
- Published October 14, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
RentRabbit.com.au is Australia’s leading crowd-sourced review and content platform for use by Tenants, Landlords and Agents. It describes itself as different from typical review platforms by providing industry leading and independent insights which can be benchmarked – allowing for a more meaningful and comparable dataset. Additionally, it provides deeper engagement tools and services allowing agencies to access the entire renter and landlord lifecycles. Consumers are demanding product and service transparency and property is the next frontier – that’s why thousands of Aussie’s are turning to Rent Rabbit to guide them towards a rental decision that’s right for them.
Company Highlights
- “The New Game-Changing Review Platform For Renters” – A Current Affair, Nine Network.
- Over 2 million properties listed for reviews.
- 55,000 website views and over 17,000 properties searched on the website since February MVP launch.
- The company has grown a strong social media presence increasing Instagram followers 1,317% in a few weeks and also on national television and most mainstream media outlets (etc A Current Affair, Brisbane 97.3, The Edge 96.1, etc.).
- In discussions with property management companies and leading real estate representatives regarding strategic affiliations and referral agreements.
- Private investors who have participated have backgrounds ranging from Investment Banking, Property and Data Management, Fintech, Wealth Management, and Venture Capital.
- Current investors are across Australia and New Zealand, understanding the challenge is global.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
